Journal Mobile Options
Table of Contents
Vol. 27, No. 3, 2009
Issue release date: March 2009
Cerebrovasc Dis 2009;27:254–258

Utilization of Intravenous Tissue Plasminogen Activator for Ischemic Stroke: Are There Sex Differences?

Allen N.B. · Myers D. · Watanabe E. · Dostal J. · Sama D. · Goldstein L.B. · Lichtman J.H.
aSection of Chronic Disease Epidemiology, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Conn., bUHC University HealthSystem Consortium, Oak Brook, Ill., cDepartment of Medicine (Neurology), Duke Center for Cerebrovascular Disease, Center for Clinical Health Policy Research, Duke University and Durham VAMC, Durham, N.C., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: We evaluated whether there were sex-related differences in the administration of intravenous tissue plasminogen activator (IV-tPA) to patients with acute ischemic stroke admitted to US academic medical centers. Methods: Medical records were abstracted for consecutive ischemic stroke patients admitted to 32 academic medical centers from January through June, 2004, as part of the University HealthSystem Consortium Ischemic Stroke Benchmarking Project. Multivariate logistic models were used to test for sex-related differences in the receipt of IV-tPA with adjustment for demographic and clinical factors. Results: The study included 1,234 patients (49% women; mean age 66.6 years; 56% white). IV-tPA was given to 7% (6.5% of women versus 7.5% of men, p = 0.49). Women and men were equally likely to receive IV-tPA in risk-adjusted analyses (OR 1.02, 95% CI 0.64–1.64). Approximately 77% of women and men who did not receive IV-tPA did not meet the 3-hour treatment window or their time of onset was unknown. Conclusions: Women admitted to academic hospitals receive IV-tPA as often as men; however, a substantial percentage of both women and men are not arriving within the 3-hour time window required for diagnostic assessment and administration of intravenous thrombolytic therapy. Additional efforts are needed to improve the rapid identification, evaluation and treatment of stroke patients.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Wardlaw JM, Zoppo G, Yamaguchi T, Berge E: Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003:CD000213.
  2. Adams HP Jr, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, Grubb RL, Higashida R, Kidwell C, Kwiatkowski TG, Marler JR, Hademenos GJ: Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003;34:1056–1083.
  3. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP: National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39:924–928.
  4. Deng YZ, Reeves MJ, Jacobs BS, Birbeck GL, Kothari RU, Hickenbottom SL, Mullard AJ, Wehner S, Maddox K, Majid A: IV tissue plasminogen activator use in acute stroke: Experience from a statewide registry. Neurology 2006;66:306–312.
  5. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG: Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001;32:1832–1840.
  6. Johnston SC, Fung LH, Gillum LA, Smith WS, Brass LM, Lichtman JH, Brown AN: Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: The influence of ethnicity. Stroke 2001;32:1061–1068.
  7. Reid JM, Dai D, Gubitz GJ, Kapral MK, Christian C, Phillips SJ: Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital. Stroke 2008;39:1090–1095.
  8. Gargano JW, Wehner S, Reeves M: Sex differences in acute stroke care in a statewide stroke registry. Stroke 2008;39:24–29.
  9. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM: Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004;61:346–350.
  10. Reynolds PS, Crenshaw CT, Lefkowitz DS, Shelton BJ, Preisser JS, Tegeler CH: A practical stroke severity scale predicts hospital outcomes. J Stroke Cerebrovasc Dis 2001;10:231–235.
  11. Hills NK, Johnston SC: Why are eligible thrombolysis candidates left untreated? Am J Prev Med 2006;31:S210–S216.
  12. California Acute Stroke Pilot Registry (CASPR) Investigators: Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology 2005;64:654–659.

    External Resources

  13. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, Alwell K, Gebel J, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Shukla R, Broderick JP: Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: A population-based study. Stroke 2004;35:e27–e29.
  14. Bateman BT, Schumacher HC, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, Pile-Spellman J: Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: An analysis of the nationwide inpatient sample 1999 to 2002. Stroke 2006;37:440–446.
  15. Qureshi AI, Suri MF, Nasar A, He W, Kirmani JF, Divani AA, Prestigiacomo CJ, Low RB: Thrombolysis for ischemic stroke in the United States: data from national hospital discharge survey 1999–2001. Neurosurgery 2005;57:647–654; discussion 647–654.
  16. Brown DL, Lisabeth LD, Garcia NM, Smith MA, Morgenstern LB: Emergency department evaluation of ischemic stroke and TIA: The basic project. Neurology 2004;63:2250–2254.
  17. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, Hammel JP, Qu A, Sila CA: Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000;283:1151–1158.
  18. Birbeck GL, Cui X, Zingmond DS, Vickrey BG: Intravenous tissue plasminogen activator for acute stroke in California: recipients and resources. Cerebrovasc Dis 2004;17:341–343.
  19. Kapral MK, Fang J, Hill MD, Silver F, Richards J, Jaigobin C, Cheung AM: Sex differences in stroke care and outcomes: Results from the registry of the Canadian stroke network. Stroke 2005;36:809–814.
  20. Morgenstern LB, Staub L, Chan W, Wein TH, Bartholomew LK, King M, Felberg RA, Burgin WS, Groff J, Hickenbottom SL, Saldin K, Demchuk AM, Kalra A, Dhingra A, Grotta JC: Improving delivery of acute stroke therapy: The TLL Temple Foundation Stroke Project. Stroke 2002;33:160–166.
  21. Alberts MJ, Perry A, Dawson DV, Bertels C: Effects of public and professional education on reducing the delay in presentation and referral of stroke patients. Stroke 1992;23:352–356.
  22. Morgenstern LB, Bartholomew LK, Grotta JC, Staub L, King M, Chan W: Sustained benefit of a community and professional intervention to increase acute stroke therapy. Arch Intern Med 2003;163:2198–2202.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50